Tim Boreham sharpens his knifes to look under the hood at cardiac pacing device innovator EBR Systems after its US FDA ...

The US Food & Drug Administration has approved EBR System's leadless pacemaker WISE, the only device able to deliver left-ventricle ... Read More The post Health Check: With the FDA’s tick(er) of ...

Cardiac tamponade necessitating intraoperative pericardiocentesis occurred in one patient due to perforation of a right ventricular lead. Coronary ... device for cardiac resynchronization therapy ...

In the absence of randomized trials, data are contradictory on the benefits of adding defibrillation therapy to CRT ... coronary sinus. Therefore, the guidelines acknowledge that the assessment of ...

To review the critical role of key pharmacological therapies and implanted cardiac devices in reducing morbidity ... or combined with an ICD (CRT-D). The procedure involves delivering an LV lead via ...

Defining the Length of Stay Following Percutaneous Coronary Intervention Catheterization ... Training Pathways for Implantation of Cardioverter-Defibrillators and Cardiac Resynchronization Therapy ...

Despite the positive results, there are open questions about LBB pacing, including long-term lead performance. RCTs are ...

EBR Systems, Inc. (ASX: EBR), a $12.59 billion market cap medical device company with ... ineligible for conventional CRT due to anatomical challenges, previous lead failures, or high procedural ...

Omniasecure, which was authorized for placement in the heart’s right ventricle, is the world’s smallest defibrillation lead, ...

In patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI), stenting demonstrated improved long-term survival and fewer cardiac arrests at one year. The ...